Advertisement
U.S. markets closed

Infinity Pharmaceuticals, Inc. (INFIQ)

Other OTC - Other OTC Delayed Price. Currency in USD
0.00000.0000 (0.00%)
At close: 03:43PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0000
Open0.0000
BidN/A x N/A
AskN/A x N/A
Day's Range0.0000 - 0.0000
52 Week Range0.0000 - 0.5800
Volume10,500
Avg. Volume263,241
Market Cap90
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-0.4600
Earnings DateMar 26, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INFIQ

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Infinity Pharmaceuticals, Inc.
    Analyst Report: AbbVie Inc.AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
    Rating
    Fair Value
    Economic Moat
    yesterdayMorningstar
View more
  • We're sorry we weren't able to find anything about this topic.